Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
CXCR4 antagonist |
| gptkbp:approvedBy |
gptkb:FDA
leukemia multiple myeloma |
| gptkbp:ATCCode |
L03AX16
|
| gptkbp:CASNumber |
155148-31-5
|
| gptkbp:category |
orphan drug
immunostimulant |
| gptkbp:chemicalFormula |
C14H22N8
|
| gptkbp:developedBy |
AnorMED
|
| gptkbp:firstDescribed |
1994
|
| https://www.w3.org/2000/01/rdf-schema#label |
AMD3100
|
| gptkbp:IUPACName |
1,1′-[1,4-phenylenebis(methylene)]bis(1,4,8,11-tetraazacyclotetradecane)
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Genzyme
|
| gptkbp:mechanismOfAction |
blocks CXCR4 receptor
|
| gptkbp:molecularWeight |
502.58 g/mol
|
| gptkbp:otherName |
gptkb:plerixafor
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
headache
injection site reactions gastrointestinal disturbance |
| gptkbp:target |
gptkb:CXCR4
|
| gptkbp:usedFor |
hematopoietic stem cell mobilization
|
| gptkbp:bfsParent |
gptkb:CXCR4_co-receptor
gptkb:CXCR4 |
| gptkbp:bfsLayer |
7
|